A hypoxia-responsive prodrug for specific drug release and synergistic chemo-photodynamic cancer therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
3. Current challenges in cancer treatment10.1016/j.clinthera.2016.03.026 ↗
4. Cancer therapy with antibodies10.1038/s41568-024-00690-x ↗
5. Radiopharmaceutical therapy in cancer: clinical advances and challenges10.1038/s41573-020-0073-9 ↗
6. Rational combinations of targeted cancer therapies: background, advances and challenges10.1038/s41573-022-00615-z ↗
7. Photodynamic therapy for cancer10.1038/nrc1071 ↗
8. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
9. Recent advancement in photosensitizers for photodynamic therapy10.1016/j.dyepig.2024.112262 ↗
10. Fluorescent dyes based on rhodamine derivatives for bioimaging and therapeutics: recent progress, challenges, and prospects10.1039/D2CS00799A ↗
11. Recent advances for enhanced photodynamic therapy: from new mechanisms to innovative strategies10.1039/D3SC07006A ↗
12. N-bridging tetra-substituted zinc(II) phthalocyanines with Q-band absorption up to 780 nm and eminent photosensitizing activities for photodynamic therapy10.1016/j.dyepig.2024.112169 ↗
13. Self-assembled ruthenium–amino acid conjugates enable endoplasmic reticulum–nucleus Cascade targeting for cell pyroptosis and DNA destruction10.1002/adma.202508713 ↗
14. A switchable phototherapeutic strategy based on a hypoxia-responsive photosensitizer for heterogeneous tumor ablation10.1016/j.dyepig.2022.110217 ↗
15. A dual-locked activatable phototheranostic probe for biomarker-regulated photodynamic and photothermal cancer therapy10.1002/anie.202202966 ↗
16. Rational design of mesoporous coordination polymer nanophotosensitizers for photodynamic tumor ablation10.1021/acsami.2c22095 ↗
17. An NIR-II photothermally triggered “Oxygen Bomb” for hypoxic tumor programmed Cascade therapy10.1002/adma.202201978 ↗
18. A self-catalytic NO/O2 gas-releasing nanozyme for radiotherapy sensitization through vascular normalization and hypoxia relief10.1002/adma.202403921 ↗
19. Hypoxia-tolerant polymeric photosensitizer prodrug for cancer photo-immunotherapy
20. NIR-II photoacoustic imaging-guided oxygen delivery and controlled release improves photodynamic therapy for hepatocellular carcinoma10.1002/adma.202308780 ↗
21. Activatable nano-photosensitizers for precise photodynamic cancer therapy10.1016/j.ccr.2023.215324 ↗
22. Conquering the hypoxia limitation for photodynamic therapy10.1002/adma.202103978 ↗
23. The current status of photodynamic therapy in cancer treatment10.3390/cancers15030585 ↗
24. Self-disassembling and oxygen-generating porphyrin-lipoprotein nanoparticle for targeted glioblastoma resection and enhanced photodynamic therapy10.1002/adma.202307454 ↗
25. Amphiphilic fluorinated Aza-BODIPY alleviates hypoxia in solid tumors and enhances the photodynamic efficacy for breast cancer10.1016/j.bioorg.2025.109101 ↗
26. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose10.7150/thno.25409 ↗
27. Lonidamine liposomes to enhance photodynamic and photothermal therapy of hepatocellular carcinoma by inhibiting glycolysis10.1186/s12951-023-02260-z ↗
28. Activatable type I photosensitizer with quenched photosensitization pre and post photodynamic therapy10.1002/anie.202307288 ↗
29. Strategic design of conquering hypoxia in tumor for advanced photodynamic therapy10.1002/adhm.202300530 ↗
30. Precise gliomas therapy: hypoxia-activated prodrugs sensitized by nano-photosensitizers10.1016/j.biomaterials.2022.121770 ↗
31. An activatable phototheranostic probe for anti-hypoxic type I Photodynamic- and immuno-therapy of cancer10.1002/adma.202305243 ↗
32. Two-photon-activated heavy-atom free AIEgen for highly efficient type I photodynamic therapy10.1002/adfm.202410202 ↗
33. Targeting Warburg effect to rescue the suffocated photodynamic therapy: a cancer-specific solution10.1016/j.biomaterials.2023.122017 ↗
34. Bioorthogonal chemistry and illumination controlled programmed size-changeable nanomedicine for synergistic photodynamic and hypoxia-activated therapy10.1016/j.biomaterials.2022.121480 ↗
35. Basic structural modifications for improving the practical properties of BODIPY10.1016/j.ccr.2022.214684 ↗
36. BODIPY as a multifunctional theranostic reagent in biomedicine: self-assembly, properties, and applications10.1002/adma.202207546 ↗
37. Heavy-atom-modulated supramolecular assembly increases antitumor potency against malignant breast tumors via tunable cooperativity10.1002/adma.202004225 ↗
38. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment10.1002/anie.202008732 ↗
39. BODIPY-based probes for hypoxic environments10.1016/j.ccr.2023.215041 ↗
40. Hypoxia-responsive nano-photosensitizer anchored by PEGylated BODIPY: a single-laser-driven platform for photo-enhanced synergistic chemo/photodynamic/photothermal cancer therapy10.1021/acs.molpharmaceut.5c00646 ↗
41. Breaking the myth of enzymatic azoreduction10.1021/acschembio.4c00779 ↗
42. Nature-inspired photocatalytic azo bond cleavage with red light10.1021/jacs.3c09837 ↗
43. A hypoxia-activated prodrug conjugated with a BODIPY-based photothermal agent for imaging-guided chemo-photothermal combination therapy10.1021/acsami.2c09071 ↗
44. Bioorthogonal Turn-On BODIPY-peptide photosensitizers for tailored photodynamic therapy10.1002/chem.202001718 ↗
45. Mitochondrion-targeting PEGylated BODIPY dyes for near-infrared cell imaging and photodynamic therapy10.1039/D1TB02393D ↗
46. Enzyme-activated multifunctional prodrug combining site-specific chemotherapy with light-triggered photodynamic therapy10.1021/acs.molpharmaceut.1c00761 ↗